Ultragenyx
RARE
$44.24
Share price
0.89%
Change (1 day)
4.19%
Change (1 year)
Categories
Ultragenyx (RARE) - P/B ratio
P/B ratio as of April 2024 : 13.2
According to Ultragenyx's latest financial reports the company has a price-to-book ratio of 13.2.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Ultragenyx - P/B ratio (from 2014 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 14.3 | 54.73% |
| 2022-12-31 | 9.21 | 48.31% |
| 2021-12-31 | 6.21 | -21.69% |
| 2020-12-31 | 7.93 | 109.96% |
| 2019-12-31 | 3.78 | 4.04% |
| 2018-12-31 | 3.63 | -29.5% |
| 2017-12-31 | 5.15 | -15.01% |
| 2016-12-31 | 6.06 | -26.2% |
| 2015-12-31 | 8.21 | 8.4% |
| 2014-12-31 | 7.58 | |
| 2013-12-31 | N/A | |
| 2012-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Lexicon Pharmaceuticals
LXRX | 2.79 | -78.91% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -0.7910 | -105.98% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | 19.0 | 43.83% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 3.11 | -76.51% | 🇺🇸 USA |